Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sezary Syndrome 3 Mycosis Fungoides 3 Lymphoma, T-Cell, Cutaneous 3 Skin Neoplasms 2 Lymphoma 2 Melanoma 1 Lymphoma, T-Cell 1 Kidney Neoplasms 1

Interventions

Cyclophosphamide 32 Etoposide 18 romidepsin 17 fludarabine 17 Vincristine 17 Doxorubicin 16 Rituximab 14 Prednisone 14 Melphalan 14 Gemcitabine 13 Brentuximab Vedotin 13 Lenalidomide 12 Peripheral Blood Stem Cell Transplantation 11 Cytarabine 11 Whole-Body Irradiation 10 Biopsy 10 10-propargyl-10-deazaaminopterin 10 pembrolizumab 9 fludarabine phosphate 9 Specimen Handling 9 Busulfan 9 Mycophenolic Acid 8 Granulocyte Colony-Stimulating Factor 8 Depsipeptides 8 Carmustine 8 Bortezomib 8 duvelisib 7 Vorinostat 7 Methotrexate 7 Magnetic Resonance Spectroscopy 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, T-Cell × zanolimumab × Clear all

NCT00877656 2024-03-18

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

Emergent BioSolutions

Phase 2/3 Completed

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡